Results 141 to 150 of about 9,765 (234)

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy

Drug Design, Development and Therapy, 2019
Thomas G Cotter,1 Donald M Jensen21Center for Liver Diseases, The University of Chicago Medicine, Chicago, IL, USA; 2Section of Hepatology, RUSH University Medical Center, Chicago, IL, USAAbstract: Direct-acting antiviral (DAA) therapy has changed the ...
Cotter TG, Jensen DM
doaj  

Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. [PDF]

Antimicrob Agents Chemother, 2015
Liu R, Curry S, McMonagle P, Yeh WW, Ludmerer SW, Jumes PA, Marshall WL, Kong S, Ingravallo P, Black S, Pak I, DiNubile MJ, Howe AY.   +12 more
europepmc   +1 more source

Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons. [PDF]

Antimicrob Agents Chemother, 2017
Asante-Appiah E, Curry S, McMonagle P, Ingravallo P, Chase R, Nickle D, Qiu P, Howe A, Lahser FC.   +8 more
europepmc   +1 more source

In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir. [PDF]

Antimicrob Agents Chemother, 2016
Cheng G, Tian Y, Doehle B, Peng B, Corsa A, Lee YJ, Gong R, Yu M, Han B, Xu S, Dvory-Sobol H, Perron M, Xu Y, Mo H, Pagratis N, Link JO, Delaney W.   +16 more
europepmc   +1 more source

Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events. [PDF]

Oncotarget, 2018
Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Moriyama M, Kato N.   +17 more
europepmc   +1 more source

Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects. [PDF]

Antimicrob Agents Chemother, 2017
Mogalian E, German P, Kearney BP, Yang CY, Brainard D, Link J, McNally J, Han L, Ling J, Mathias A.   +9 more
europepmc   +1 more source

Potential Drug Interactions in Psychiatric Patients Undergoing Pangenotypic Therapy for Hepatitis C Virus Infection. [PDF]

Pharmaceuticals (Basel)
Dybowska D, Pawłowska M, Kozielewicz D.
europepmc   +1 more source

Hepatitis C Virus NS5A Inhibits YAP1-HSC70 Interaction, Thereby Preventing YAP1 Degradation Via Chaperone-Mediated Autophagy. [PDF]

Kobe J Med Sci
Septianastiti MA, Matsui C, Xu Z, Puspitasari F, Deng L, Abe T, Shoji I.   +6 more
europepmc   +1 more source

Screening and Characterization of TAT-Fused Nanobodies Targeting Bovine Viral Diarrhea Virus NS3/NS5A for Antiviral Application. [PDF]

Biomolecules
Dong Q, Xiao Y, Liu Z, Zhang W, Wu A, Zhang H, Sheng J.   +6 more
europepmc   +1 more source

High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection. [PDF]

Liver Int, 2016
Poordad F, Landis CS, Asatryan A, Jackson DF, Ng TI, Fu B, Lin CW, Yao B, Kort J.   +8 more
europepmc   +1 more source